Industry
Biotechnology
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 23, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:40 pm
Portfolio Pulse from Vandana Singh
June 28, 2024 | 3:41 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 1:01 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 11:03 am
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 8:10 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 8:03 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 8:02 pm
Portfolio Pulse from Benzinga Newsdesk
June 06, 2024 | 10:49 am
Portfolio Pulse from Benzinga Newsdesk
May 24, 2024 | 4:56 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.